Results 81 to 90 of about 286,424 (258)

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review

Infectious Diseases and Therapy
Viral hepatitis remains a significant challenge for global public health and a leading cause of liver-related morbidity and mortality worldwide, with most cases caused by five hepatotropic viruses: hepatitis A, B, C, D, and E.
He-ming Sun, Xing-yu Wang, Hong-qin Xu, Yan-hang Gao   +3 more
doaj   +1 more source

Hepatitis Vaccines: Recent Advances and Challenges

Vaccines
Viral hepatitis constitutes a substantial global public health challenge. The etiological agents, referred to as hepatitis viruses, are primarily categorized into five types: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV ...
Mei Lu, Yakun Liu, Lele Li, Xueke Liu, Bin Wu, Yingping Wu   +5 more
doaj   +1 more source

Targeting Nupr1‐Mediated p53 Mitochondrial Sequestration Alleviates Aortic Dissection by Restoring the Gadd45b‐Dependent Survival Program

Advanced Science, EarlyView.
This study identifies Nupr1 as a crucial stress‐responsive orchestrator driving AD. Under severe stress, Nupr1 massively accumulates within mitochondria to sequester p53, triggering apoptosis and concurrently repressing the Gadd45b‐mediated survival program.
Xi Yang, Ke‐Yuan Chen, Yue Tian, Zong‐Sheng Jiang, Jian Lei, Xing‐Hui Zhuang, Jiang‐Bin Wu, Le‐Le Tang, Hao‐Yu Li, Xiao‐Hui Chen, Yue Wang, Yu‐Mei Li, Zhi‐Huang Qiu, Zi‐Wen Cai, Liang‐Wan Chen   +14 more
wiley   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Therapeutic, preventive, and pathogenetic advances in viral hepatitis

Frontiers in Cellular and Infection Microbiology
Viral hepatitis and associated liver injury represent a major global public health concern, capable of progressing to chronic liver disease, cirrhosis, and hepatocellular carcinoma.
Hong Jiang, Yi-fan Zhang, Ru-chao Zhang, Ya-nan Xing   +3 more
doaj   +1 more source

Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS

Advanced Science, EarlyView.
Lipid stress drives O‐GlcNAcylation of the m6A demethylase FTO at Ser195, enhancing its stability and demethylase activity. This modification removes m6A from HRAS mRNA, preventing its degradation and activating PI3K/AKT signaling to promote hepatic steatosis and inflammation.
Jia‐Xin Yin, Yan‐Lai Zhang, Qun Liu, Rui Liu, Hai‐Yang Yuan, Sui‐Dan Chen, Ming‐Hua Zheng, Kai Wang, Ni Tang, Ai‐Long Huang   +9 more
wiley   +1 more source

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice

Hepatology, EarlyView., 2022
Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim, Jaewoong Lee, Hyun Joo Shin, Eun Ae Jeong, Hye Min Jang, Yu Jeong Ahn, Hyeong Seok An, Jong Youl Lee, Meong Cheol Shin, Soo Kyoung Kim, Won Gi Yoo, Won Ho Kim, Gu Seob Roh   +12 more
wiley   +1 more source

A Biomimetic cRGDyk‐Engineered Platelet Nanoplatform for ACAD11 Delivery to Trigger Pyroptosis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
A biomimetic platelet nanoplatform (OE‐ACAD11@R‐PLT) is developed for targeted hepatocellular carcinoma immunotherapy. By selectively delivering therapeutic plasmids, this system induces mitochondrial dysfunction and triggers robust NLRP3/Caspase‐1/GSDMD‐mediated pyroptosis in tumor cells.
Hongyi Bao, Wei Feng, Wei Zong, Yi Li, Xinyue Qin, Xinyue Wang, Yubo Yang, Guanhua Chen, Yiting Hou, Xuan Tan, Lin Chen, Ming Zhang, Feng Wang   +12 more
wiley   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source